Emmaus Life Sciences Files 8-K on Financials

TL;DR

Emmaus Life Sciences dropped an 8-K on Nov 19th covering financials - check it out.

AI Summary

Emmaus Life Sciences, Inc. filed an 8-K on November 19, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The company, formerly known as MYnd Analytics, Inc., CNS RESPONSE, INC., and STRATIVATION, INC., is incorporated in Delaware and based in Torrance, California.

Why It Matters

This filing provides crucial updates on Emmaus Life Sciences' financial performance and condition, which is essential for investors to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of financial information and does not indicate any immediate or significant risks.

Key Players & Entities

• Emmaus Life Sciences, Inc. (company) — Registrant
• November 19, 2024 (date) — Date of earliest event reported
• MYnd Analytics, Inc. (company) — Former company name
• CNS RESPONSE, INC. (company) — Former company name
• STRATIVATION, INC. (company) — Former company name
• 21250 Hawthorne Boulevard, Suite 800, Torrance, CA 90503 (address) — Business and mailing address

FAQ

Filing Documents

• ea0221824-8k_emma.htm (8-K) — 26KB
• ea022182401ex99-1_emma.htm (EX-99.1) — 45KB
• ex99-1_001.jpg (GRAPHIC) — 4KB
• 0001213900-24-100231.txt ( ) — 249KB
• emma-20241119.xsd (EX-101.SCH) — 3KB
• emma-20241119_lab.xml (EX-101.LAB) — 33KB
• emma-20241119_pre.xml (EX-101.PRE) — 22KB
• ea0221824-8k_emma_htm.xml (XML) — 3KB

02 Results of Operation and Financial Condition

Item 2.02 Results of Operation and Financial Condition. On November 19, 2024, Emmaus Life Sciences, Inc. ("we," "us," "our," "Emmaus" or the "company") issued a press release announcing its results of operations and financial condition as of and for the three and nine months ended June 30, 2024, a copy of which is included as Exhibit 99.1 to this Current Report and incorporated herein by reference. The information included in this Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 ("Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits See the accompanying Index to Exhibits, which is incorporated herein by reference. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 19, 2024 Emmaus Life Sciences, Inc. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2 INDEX TO EXHIBITS Exhibit Number Description 99.1 November 19, 2024 press release 104 Cover Page Interactive Date File (embedded within Inline XBRL document) 3

View Full Filing

View this 8-K filing on SEC EDGAR